Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort

BACKGROUND: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMD) receiving mycophenolic acid (MPA) may have a less favourable outcome from COVID-19 infection. Our aim was to investigate whether MPA treatment is associated with severe infection and/or death. METHODS: IRMD patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Truchetet, Marie-Elise, Drumez, Elodie, Barnetche, Thomas, Martin, Claire, Devaux, Mathilde, Goulenok, Tiphaine, Maria, Alexandre, Schmidt, Jean, Abdallah, Nassim Ait, Melki, Isabelle, Hachulla, Eric, Richez, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Connective Tissue Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485642/
https://www.ncbi.nlm.nih.gov/pubmed/36113962
http://dx.doi.org/10.1136/rmdopen-2022-002476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485642/
https://www.ncbi.nlm.nih.gov/pubmed/36113962
http://dx.doi.org/10.1136/rmdopen-2022-002476

Ejemplares similares